StonvexLoading…
StonvexStonvexStonvexCore line items from NMR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-03-31 | Annual 2024 2024-03-31 | Annual 2023 2023-03-31 | Annual 2022 2022-03-31 |
|---|---|---|---|---|
Revenue | ¥1.07T | ¥896.49B | ¥707.94B | ¥790.79B |
Operating Income | ¥473.51B | ¥284.19B | ¥179.75B | ¥221.00B |
Net Income | ¥340.74B | ¥165.86B | ¥92.79B | ¥143.00B |
EPS (Diluted) | ¥111.03 | ¥52.69 | ¥29.74 | ¥45.23 |
Total Assets | ¥56.80T | ¥55.15T | ¥47.77T | ¥43.41T |
Total Liabilities | ¥53.22T | ¥51.70T | ¥44.55T | ¥40.44T |
Cash & Equivalents | ¥4.42T | ¥4.24T | ¥3.82T | ¥3.32T |
Free Cash Flow OCF − CapEx | ¥-868.58B | ¥-13.14B | ¥-865.99B | ¥-974.16B |
Shares Outstanding | 2.96B | 2.97B | 3.00B | 3.02B |